Literature DB >> 9816315

Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.

Y Ohta1, Y Endo, M Tanaka, J Shimizu, M Oda, Y Hayashi, Y Watanabe, T Sasaki.   

Abstract

The expression of mRNAs for vascular endothelial growth factor (VEGF) was examined in 42 cases of primary lung cancer tissues (18 adenocarcinomas, 18 squamous cell carcinomas, 2 large cell carcinomas, 3 small cell carcinomas, and 1 adenoid cystic carcinoma) and 4 human lung cancer cell lines. As seen by reverse transcription-PCR analysis, VEGF mRNAs were expressed predominantly as transcripts for the secretory forms of VEGF (VEGF121 and VEGF165), both in resected lung cancer tissues and in human lung cancer cell lines. The positive ratios of VEGF mRNA according to pathological type were 66.7% (12 of 18) in adenocarcinoma, 72.2% (13 of 18) in squamous cell carcinoma, 100% (2 of 2) in large cell carcinoma, and 67% (2 of 3) in small cell carcinoma. The relative antigen levels of VEGF detected by immunohistochemical examination almost coincided with the relative VEGF mRNA expression levels. Also, we examined the expression of basic fibroblast growth factor mRNA in the same tumor specimens. However, no significant correlation was found between the VEGF and basic fibroblast growth factor mRNA expression levels. We assessed the relationship between the VEGF121 mRNA expression level and the survival period in patients (n = 17) who underwent a curative operation at stage I of the disease. The median survival of the VEGF high-expression group was 8 months, and that of the VEGF low-expression group was 151 months. The 3- and 5-year survival rates of the high-expression group (n = 6) were 50.0% and 16.7%, respectively. On the other hand, those of the low expression group (n = 11) were 90.9% and 77.9%, respectively. The difference in survival between the two groups was significant (P < 0.05). Among eight cases of long-term survival beyond 5 years, seven cases had low or no VEGF121 mRNA expression. In contrast, among 18 cases with VEGF121 mRNA overexpression, 17 cases died due to recurrence. As a marker of tumor angiogenesis, the VEGF121 mRNA expression level may be a significant prognostic indicator of lung cancers in early stages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816315

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

1.  IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.

Authors:  Tatiana Correa Carneiro-Lobo; Luiza Coimbra Scalabrini; Leila da Silva Magalhães; Laura B Cardeal; Felipe Silva Rodrigues; Edmilson Ozorio Dos Santos; Albert S Baldwin; Elena Levantini; Ricardo J Giordano; Daniela Sanchez Bassères
Journal:  Lung Cancer       Date:  2019-02-25       Impact factor: 5.705

2.  Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.

Authors:  K Takayama; P N Reynolds; Y Adachi; L Kaliberova; J Uchino; Y Nakanishi; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-10-06       Impact factor: 5.987

3.  Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.

Authors:  Benjamin S Jones; Mary S Jerome; Deborah Miley; Bradford E Jackson; Mollie R DeShazo; Vishnu V B Reddy; Karan P Singh; Olivia C Brown; Francisco Robert
Journal:  Lung Cancer       Date:  2017-02-09       Impact factor: 5.705

Review 4.  Molecular pathology of tumor metastasis. I. Predictive pathology.

Authors:  J Tímár; O Csuka; Z Orosz; A Jeney; L Kopper
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion.

Authors:  Mustafa Teoman Yanmaz; Sebnem Izmır Guner; Bahar Satılmıs; Huseyın Akyol; Mehmet Akıf Aydın
Journal:  Med Oncol       Date:  2014-10-08       Impact factor: 3.064

6.  Diversity of the angiogenic phenotype in non-small cell lung cancer.

Authors:  Marc R McClelland; Shannon L Carskadon; Liujian Zhao; Eric S White; David G Beer; Mark B Orringer; Allan Pickens; Andrew C Chang; Douglas A Arenberg
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

7.  CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; T Schmid; E Gunsilius; G Hilbe; E Wöll; C M Kähler
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

Review 8.  Targeting angiogenesis in squamous non-small cell lung cancer.

Authors:  Bilal Piperdi; Amartej Merla; Roman Perez-Soler
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

9.  Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma.

Authors:  M Ioannou; R Papamichali; E Kouvaras; I Mylonis; D Vageli; T Kerenidou; S Barbanis; A Daponte; G Simos; K Gourgoulianis; G K Koukoulis
Journal:  Lung       Date:  2009-08-26       Impact factor: 2.584

10.  Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation.

Authors:  Mao Xiu Zhang; Xu Zhao; Zhi Gang Wang; Wei Ming Zhao; Yun Shan Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.